Denosumab for the treatment of osteoporosis

Bibliography

• Wright N, Looker A, Saag K, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014;29(10):2520–6
   PubMedGoogle Scholar
• Burge R, Dawson-Hughes B, Solomon D, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22(3):465–75
   PubMed Web of Science ®Google Scholar
• Hannan E, Magaziner J, Wang J, et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA 2001;285:2736–42
   PubMed Web of Science ®Google Scholar
• Cooper C, Atkinson EJ, Jacobsen SJ. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001–5
   PubMed Web of Science ®Google Scholar
• Roux C, Wyman A, Hooven F, et al. Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women. Osteoporos Int 2012;23(12):2863–71
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Looker A, Tosteson A, et al. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 2010;21(1):41–52
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General; 2004
   Google Scholar
• Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007;82(12):1493–501
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee 2011
   Google Scholar
• Liberman U, Weiss S, Broll J, et al. Effects of oral alendronate on bone mineral denisty and the incidence of fracture in postmenopausal osteoporosis. N Engl J Med 1995;333(22):1437–43
   PubMed Web of Science ®Google Scholar
• Mcclung M, Geusens P, Miller P, et al. Effects of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344(5):333–40
   PubMed Web of Science ®Google Scholar
• Chestnut CI, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8):1241–9
   PubMed Web of Science ®Google Scholar
• Black D, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809–22
   PubMed Web of Science ®Google Scholar
• Chestnut CI, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109(4):267–76
   PubMed Web of Science ®Google Scholar
• Rossouw J, Anderson G, Prentice R, et al. Risks and benefits of estrogen plus protestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321–33
   PubMed Web of Science ®Google Scholar
• Anderson G, Limacher M, Assaf A, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291(14):1701–12
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black D, Mitlak B, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282(7):637–45
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher J, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92(3):1045–52
   Google Scholar
• Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434–41
   PubMed Web of Science ®Google Scholar
• Cummings S, San Martin J, Mcclung M, et al. Denosumab for prevention of fractures in postmenpausal women with osteoporosis. N Engl J Med 2009;361(8):756–65
   PubMed Web of Science ®Google Scholar
• O’Donnell S, Cranney A, Wells G, et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006;19(3):CD005326
   Google Scholar
• Greenspan S, Bone H, Ettinger M, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146(5):326
   PubMed Web of Science ®Google Scholar
• Bone H, McClung M, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010;25(5):937–47
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26(1):19–26
   PubMed Web of Science ®Google Scholar
• Recker R, Benson C, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Amgen, Inc. Prolia (denosumab) prescribing information. 2010; updated 2014
   Google Scholar
• Bekker P, Holloway D, Rasmussen A, et al. A single-dose placebo-controlled study of AMG 162, a fully monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059–66
   PubMed Web of Science ®Google Scholar
• Sutjandra L, Rodriguez R, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 2011;50(12):793–807
   PubMed Web of Science ®Google Scholar
• Block G, Bone H, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012;27(7):1471–9
   PubMed Web of Science ®Google Scholar
• Miller P, Bolognese M, Lewiecki E, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43(2):222–9
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension. ASBMR 2013 Annual Meeting; 2013. Oral Poster Session; Presentation Number: LB-MO26
   Google Scholar
• Brown J, Roux C, Torring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 2013;28(4):746–52
   PubMed Web of Science ®Google Scholar
• Brown J, Reid I, Wagman R, et al. Effects of up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: the FREEDOM Study Extension. J Bone Miner Res 2014;29(9):2051–6
   PubMed Web of Science ®Google Scholar
• Brown J, Prince R, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24(1):153–61
   PubMed Web of Science ®Google Scholar
• Kendler D, Roux C, Benhamou C, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2009;25(1):72–81
   Web of Science ®Google Scholar
• Roux C, Hofbauer L, Ho P, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 2014;58:48–54
   PubMed Web of Science ®Google Scholar
• Recknor C, Czerwinski E, Bone H, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 2013;121(6):1291–9
   PubMed Web of Science ®Google Scholar
• Orwoll E, Teglbjærg C, Langdahl B, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012;97(9):3161–9
   PubMed Web of Science ®Google Scholar
• Smith M, Egerdie B, Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361(8):745–55
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875–82
   PubMed Web of Science ®Google Scholar
• Tsai J, Uihlein A, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013;382(9886):50–6
   PubMed Web of Science ®Google Scholar
• Cosman F, Eriksen E, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J Bone Miner Res 2011;26(3):503–11
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Wyland J, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010;95(4):1838–45
   PubMed Web of Science ®Google Scholar
• Freemantle N, Satram-Hoang A, Tang E, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23(1):317–26
   PubMed Web of Science ®Google Scholar
• Yassin M, Soliman A, De Sanctis V, et al. Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis. Indian J Endocrinol Metab 2014;18(4):546–51
   PubMedGoogle Scholar
• Geller M, Wagman R, Ho P, et al. Early findings from Prolia® post-marketing safety surveillance for atypical femur fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis. Ann Rheum Dis 2014;73(Suppl2
   Google Scholar
• Bone H, Bolognese M, Yuen C, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93(6):2149–57
   PubMed Web of Science ®Google Scholar
• Bone H, Chapurlat R, Brandi M, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013;11):4483–92
   PubMed Web of Science ®Google Scholar
• Anastasilakis A, Toulis K, Goulis D, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009;41(10):721–9
   PubMed Web of Science ®Google Scholar
• von Keyserlingk C, Hopkins R, Anastasilakis A, et al. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum 2011;41(2):178–86
   PubMed Web of Science ®Google Scholar
• Hageman K, Patel K, Mace K, et al. The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann Pharmacother 2013;47(7-8):1069–74
   Google Scholar
• Henry D, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125–32
   PubMed Web of Science ®Google Scholar
• Watts N, Roux C, Modlin J, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int 2012;23(1):327–37
   PubMed Web of Science ®Google Scholar
• Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535–41
   PubMed Web of Science ®Google Scholar
• Black D, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809–22
   PubMed Web of Science ®Google Scholar